Mineralocorticoid receptor antagonists (MRAs) are highly effective therapies for cardiovascular and renal disease. However, the widespread clinical use of currently available MRAs in cardiorenal medicine is hampered by an increased risk of hyperkalemia. The mineralocorticoid receptor (MR) is a nuclear more…
Mineralocorticoid receptor (MR) antagonists are well established in the treatment of chronic left heart disease, however, there is an ever growing body of evidence suggesting potential benefits in other cardiovascular disease. Here, we evaluated the effects of MR antagonists on more…
Mineralocorticoid receptors control extracellular matrix composition in the left ventricle and also extracardiac tissues. In the present issue of Circulation Research, the group of Natalia Lopez further extend this view, demonstrating that the aldosterone/MR signaling pathway drives mitral valve remodeling more…
